Switching to KPL-387 alone for well-controlled pericarditis
Part of Heart & circulation clinical trials.
This study tests whether a new drug, KPL-387, can keep your pericarditis under control as your only treatment, after you have been stable on other medicines. It is for people whose pericarditis is well controlled now but who have had flares in the past.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your pericarditis must be well controlled right now (pain score 3 or less out of 10 and low inflammation blood test).
- You must have had at least one past pericarditis flare with high inflammation (CRP > 1 mg/dL).
- You have been on a stable dose of standard pericarditis medicines (like NSAIDs, colchicine, steroids, or certain biologics) for at least 3 months.
- You cannot have had a pericarditis flare in the last 3 months.
- You cannot have active or untreated tuberculosis, a weak immune system, HIV, recent serious infections, certain cancers, or an organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine, KPL-387, for people whose pericarditis keeps coming back despite standard treatments. It aims to see if this medicine can reduce flare-ups and help you feel better.
This trial tests if CardiolRx can help people with recurrent pericarditis (inflammation of the heart lining) who are stable on an IL-1 blocker and are planning to stop it. Researchers will see if CardiolRx can prevent a recurrence when the current treatment is tapered off.
This trial tests an experimental drug called VTX2735 for people with recurring pericarditis (inflammation around the heart). It aims to see if the drug can help reduce pain and inflammation during a flare-up.
This trial tests a new treatment called FKC289 for people whose membranous nephropathy (a kidney condition where the immune system attacks the kidney's filters) has come back or not improved with other treatments. The goal is to see if FKC289 is safe and can reduce protein in the urine, which indicates how well the kidney is working.
This study analyzes pericardial fluid (the fluid around your heart) to understand why pericarditis comes back. If you have pericarditis or other heart fluid buildup requiring drainage, or if you're having heart surgery, you may be able to participate.
This trial tests whether upadacitinib, an oral medication, is safe and effective for people with relapsing polychondritis that hasn't improved enough with standard treatments. It aims to reduce inflammation and control symptoms.
Hear when a new Recurrent Pericarditis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.